skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies

Journal Article · · Proceedings of the National Academy of Sciences of the United States of America
 [1];  [2];  [2];  [2];  [2];  [2]
  1. Beckman Research Institute of City of Hope, Duarte, CA (United States); Thomas Jefferson Univ., Philadelphia, PA (United States)
  2. Beckman Research Institute of City of Hope, Duarte, CA (United States)

Capitalizing on their extraordinary specificity, monoclonal antibodies (mAbs) have become one of the most reengineered classes of biological molecules. A major goal in many of these engineering efforts is to add new functionality to the parental mAb, including the addition of cytotoxins and imaging agents for medical applications. Herein, we present a unique peptide-binding site within the central cavity of the fragment antigen binding framework region of the chimeric, anti-epidermal growth factor receptor mAb cetuximab. We demonstrate through diffraction methods, biophysical studies, and sequence analysis that this peptide, a meditope, has moderate affinity for the Fab, is specific to cetuximab (i.e., does not bind to human IgGs), and has no significant effect on antigen binding. We further demonstrate by diffraction studies and biophysical methods that the meditope binding site can be grafted onto the anti-human epidermal growth factor receptor 2 mAb trastuzumab, and that the antigen binding affinity of the grafted trastuzumab is indistinguishable from the parental mAb. Lastly, we demonstrate a bivalent meditope variant binds specifically and stably to antigen-bearing cells only in the presence of the meditope-enabled mAbs. Collectively, this finding and the subsequent characterization and engineering efforts indicate that this unique interface could serve as a noncovalent “linker” for any meditope-enabled mAb with applications in multiple mAb-based technologies including diagnostics, imaging, and therapeutic delivery.

Research Organization:
SLAC National Accelerator Laboratory (SLAC), Menlo Park, CA (United States)
Sponsoring Organization:
USDOE Office of Science (SC)
Grant/Contract Number:
AC02-76SF00515
OSTI ID:
1135749
Report Number(s):
SLAC-REPRINT-2014-168
Journal Information:
Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, Issue 43; ISSN 0027-8424
Publisher:
National Academy of Sciences, Washington, DC (United States)Copyright Statement
Country of Publication:
United States
Language:
English
Citation Metrics:
Cited by: 39 works
Citation information provided by
Web of Science

References (32)

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies journal January 2010
Physicochemical Stability of the Antibody−Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes journal September 2010
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic MABS C225 and 425 journal May 2008
Antibody therapy of cancer journal March 2012
Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: Structural basis for recognition of B-cell receptors and superantigen activity journal May 2000
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging journal February 2011
Complex between Peptostreptococcus magnus Protein L and a Human Antibody Reveals Structural Convergence in the Interaction Modes of Fab Binding Proteins journal August 2001
Design and development of masked therapeutic antibodies to limit off-target effects: Application to anti-EGFR antibodies journal November 2009
BiTEs: bispecific antibody constructs with unique anti-tumor activity journal September 2005
Antibody fragments: Hope and hype journal January 2010
Evidence for Plasticity and Structural Mimicry at the Immunoglobulin Light Chain-Protein L Interface journal September 2002
Modulation of antibody effector function journal May 2011
Development trends for human monoclonal antibody therapeutics journal September 2010
Exchanging Murine and Human Immunoglobulin Constant Chains Affects the Kinetics and Thermodynamics of Antigen Binding and Chimeric Antibody Autoreactivity journal December 2007
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody journal October 2005
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes journal March 2011
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab journal April 2005
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab journal February 2003
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling journal July 2010
Pretargeted Molecular Imaging and Radioimmunotherapy journal January 2012
Antibody-Based Immunotherapy of Cancer journal March 2012
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index journal July 2008
Improved stability of multivalent antibodies containing the human collagen XV trimerization domain journal March 2012
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor journal November 2011
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas journal July 2006
Use of streptococcal protein G in obtaining crystals of an antibody Fab fragment in complex with a meningococcal antigen journal January 1999
Challenges in the Development and Manufacturing of Antibody–Drug Conjugates book January 2012
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer journal January 2012
Biodistribution and tumor imaging of an anti-CEA single-chain antibody–albumin fusion protein journal February 2008
Kinetics of Interaction between ADP-ribosylation Factor-1 (Arf1) and the Sec7 Domain of Arno Guanine Nucleotide Exchange Factor, Modulation by Allosteric Factors, and the Uncompetitive Inhibitor Brefeldin A journal December 2012
Vaccination With Cetuximab Mimotopes and Biological Properties of Induced Anti–Epidermal Growth Factor Receptor Antibodies journal November 2005
Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors journal November 1998

Cited By (13)

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development journal January 2015
A Platform To Enhance Quantitative Single Molecule Localization Microscopy journal September 2018
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells journal January 2015
Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli journal January 2016
Development of a High Affinity, Non-covalent Biologic to Add Functionality to Fabs journal January 2015
Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies journal February 2018
Mechanically interlocked functionalization of monoclonal antibodies journal April 2018
Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding journal January 2017
High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries journal August 2016
Computationally designed antibody–drug conjugates self-assembled via affinity ligands journal November 2019
Development of phage biopanning strategies to identify affinity peptide ligands for kappa light chain Fab fragments journal July 2019
Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics journal January 2019
Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer journal November 2016